Medical University Of South Carolina

This study tested a cold atmospheric plasma device on children aged 4-21 with warts or molluscum lesions. The device uses ionized gas to treat the lesions without heat. The trial was terminated early, so we don't have full results on how well it worked or its safety.

This study looked at whether a grape seed extract called OPC or the diabetes drug metformin could lower levels of AGEs (advanced glycation endproducts) in men with prostate cancer who are on hormone therapy. The trial planned to enroll 41 participants but was terminated early. Th…

This study tested a combination of two targeted drugs, tarloxotinib and sotorasib, in people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. Participants had already tried other treatments, including a KRAS-targeting drug, and their c…

This study tested a vaccine called PROSTVAC-V/F in 33 men who had their prostate removed due to cancer and were at high risk of the cancer returning. The goal was to see if the vaccine could keep cancer from coming back. The study was stopped early, so results are limited, but it…

This study looked at whether giving the drug octreotide for 24 hours instead of the usual 72 hours could prevent early rebleeding from esophageal varices in people with cirrhosis. The trial included 34 adults with active bleeding from varices who underwent endoscopic banding. The…

This study looked at whether having a certified therapy dog in the room helps children aged 3 to 7 feel less anxious and behave better when getting a numbing shot at the dentist. The trial was stopped early, but researchers planned to compare heart rate, oxygen levels, and behavi…

This study tested whether the sleep medication suvorexant (20 mg) could help breast cancer survivors who have trouble sleeping. Participants were postmenopausal women taking hormone-blocking drugs. The study was stopped early after enrolling only 5 people, so results are limited.

This study tested whether istradefylline, a drug already approved for motor symptoms in Parkinson's, could also improve apathy and motivation. Only 8 people enrolled before the trial was terminated early. The results are too limited to draw any conclusions.